234 related articles for article (PubMed ID: 23504229)
1. The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis.
Haenisch B; Herms S; Molderings GJ
Immunol Res; 2013 May; 56(1):155-62. PubMed ID: 23504229
[TBL] [Abstract][Full Text] [Related]
2. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
Zheng Y; Nong L; Liang L; Wang W; Li T
Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
[TBL] [Abstract][Full Text] [Related]
3. The genetic basis of mast cell activation disease - looking through a glass darkly.
Molderings GJ
Crit Rev Oncol Hematol; 2015 Feb; 93(2):75-89. PubMed ID: 25305106
[TBL] [Abstract][Full Text] [Related]
4. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A
Front Immunol; 2023; 14():1078958. PubMed ID: 37025992
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.
Sotlar K; Cerny-Reiterer S; Petat-Dutter K; Hessel H; Berezowska S; Müllauer L; Valent P; Horny HP
Mod Pathol; 2011 Apr; 24(4):585-95. PubMed ID: 21186345
[TBL] [Abstract][Full Text] [Related]
7. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
8. Mastocytosis and related disorders.
Chiu A; Orazi A
Semin Diagn Pathol; 2012 Feb; 29(1):19-30. PubMed ID: 22372203
[TBL] [Abstract][Full Text] [Related]
9. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
[TBL] [Abstract][Full Text] [Related]
10. KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.
Navarro-Navarro P; Álvarez-Twose I; Pérez-Pons A; Henriques A; Mayado A; García-Montero AC; Sánchez-Muñoz L; González-López O; Matito A; Caldas C; Jara-Acevedo M; Orfao A
Allergy; 2023 May; 78(5):1347-1359. PubMed ID: 36385619
[TBL] [Abstract][Full Text] [Related]
11. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
12. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
13. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
14. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
[TBL] [Abstract][Full Text] [Related]
15. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
[TBL] [Abstract][Full Text] [Related]
16. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis.
Berezowska S; Flaig MJ; Ruëff F; Walz C; Haferlach T; Krokowski M; Kerler R; Petat-Dutter K; Horny HP; Sotlar K
Mod Pathol; 2014 Jan; 27(1):19-29. PubMed ID: 23807778
[TBL] [Abstract][Full Text] [Related]
17. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
18. Mastocytosis.
Brockow K; Metcalfe DD
Chem Immunol Allergy; 2010; 95():110-124. PubMed ID: 20519885
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
[TBL] [Abstract][Full Text] [Related]
20. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
